Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Q1 Revenues and Losses Decrease

NEW YORK, May 15 - Lynx reported somewhat reduced first-quarter revenues today, amid an incremental increase in net losses.


The company, which has recently renewed contracts for its MPSS technology with the Institute for Systems Biology in Seattle and Millennium therapeutics, had revenues of $3.3 million for the quarter, compared to $5.0 million for the previous year's quarter. The company's losses totaled $4.0 million, compared to $3.8 million for the first quarter of last year.


Meanwhile, Lynx's R&D expenses decreased sharply year-over-year, to $3.6 million from $6.9 million for the first quarter of last year.


At the end of March, Lynx had $7.4 million in cash and cash equivalents, compared to $11.7 million at the end of December, 2002.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.